Literature DB >> 35121990

ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1.

Tong Zhang1,2, Linchong Sun3,4, Yijie Hao1, Caixia Suo3, Shengqi Shen1, Haoran Wei1, Wenhao Ma1, Pinggen Zhang1, Ting Wang1, Xuemei Gu3, Shi-Ting Li1, Zhaolin Chen2, Ronghui Yan1, Yi Zhang3, Yongping Cai5, Rongbin Zhou1, Weidong Jia2, Fang Huang6, Ping Gao7,8, Huafeng Zhang9,10.   

Abstract

α-Enolase 1 (ENO1) is a critical glycolytic enzyme whose aberrant expression drives the pathogenesis of various cancers. ENO1 has been indicated as having additional roles beyond its conventional metabolic activity, but the underlying mechanisms and biological consequences remain elusive. Here, we show that ENO1 suppresses iron regulatory protein 1 (IRP1) expression to regulate iron homeostasis and survival of hepatocellular carcinoma (HCC) cells. Mechanistically, we demonstrate that ENO1, as an RNA-binding protein, recruits CNOT6 to accelerate the messenger RNA decay of IRP1 in cancer cells, leading to inhibition of mitoferrin-1 (Mfrn1) expression and subsequent repression of mitochondrial iron-induced ferroptosis. Moreover, through in vitro and in vivo experiments and clinical sample analysis, we identified IRP1 and Mfrn1 as tumor suppressors by inducing ferroptosis in HCC cells. Taken together, this study establishes an important role for the ENO1-IRP1-Mfrn1 pathway in the pathogenesis of HCC and reveals a previously unknown connection between this pathway and ferroptosis, suggesting a potential innovative cancer therapy.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 35121990     DOI: 10.1038/s43018-021-00299-1

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


  65 in total

Review 1.  Eukaryotic chromosome DNA replication: where, when, and how?

Authors:  Hisao Masai; Seiji Matsumoto; Zhiying You; Naoko Yoshizawa-Sugata; Masako Oda
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

2.  The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.

Authors:  Daqian Xu; Zheng Wang; Yan Xia; Fei Shao; Weiya Xia; Yongkun Wei; Xinjian Li; Xu Qian; Jong-Ho Lee; Linyong Du; Yanhua Zheng; Guishuai Lv; Jia-Shiun Leu; Hongyang Wang; Dongming Xing; Tingbo Liang; Mien-Chie Hung; Zhimin Lu
Journal:  Nature       Date:  2020-04-08       Impact factor: 49.962

Review 3.  The RNA degradosome of Escherichia coli: an mRNA-degrading machine assembled on RNase E.

Authors:  Agamemnon J Carpousis
Journal:  Annu Rev Microbiol       Date:  2007       Impact factor: 15.500

Review 4.  Metabolic Kinases Moonlighting as Protein Kinases.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Trends Biochem Sci       Date:  2018-02-17       Impact factor: 13.807

5.  Posttranscriptional control of T cell effector function by aerobic glycolysis.

Authors:  Chih-Hao Chang; Jonathan D Curtis; Leonard B Maggi; Brandon Faubert; Alejandro V Villarino; David O'Sullivan; Stanley Ching-Cheng Huang; Gerritje J W van der Windt; Julianna Blagih; Jing Qiu; Jason D Weber; Edward J Pearce; Russell G Jones; Erika L Pearce
Journal:  Cell       Date:  2013-06-06       Impact factor: 41.582

6.  Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.

Authors:  Alfredo Castello; Bernd Fischer; Katrin Eichelbaum; Rastislav Horos; Benedikt M Beckmann; Claudia Strein; Norman E Davey; David T Humphreys; Thomas Preiss; Lars M Steinmetz; Jeroen Krijgsveld; Matthias W Hentze
Journal:  Cell       Date:  2012-05-31       Impact factor: 41.582

Review 7.  The Emerging Hallmarks of Cancer Metabolism.

Authors:  Natalya N Pavlova; Craig B Thompson
Journal:  Cell Metab       Date:  2016-01-12       Impact factor: 27.287

8.  The Mammalian Ribo-interactome Reveals Ribosome Functional Diversity and Heterogeneity.

Authors:  Deniz Simsek; Gerald C Tiu; Ryan A Flynn; Gun W Byeon; Kathrin Leppek; Adele F Xu; Howard Y Chang; Maria Barna
Journal:  Cell       Date:  2017-06-01       Impact factor: 41.582

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  Metabolic Enzymes Enjoying New Partnerships as RNA-Binding Proteins.

Authors:  Alfredo Castello; Matthias W Hentze; Thomas Preiss
Journal:  Trends Endocrinol Metab       Date:  2015-10-28       Impact factor: 12.015

View more
  6 in total

1.  HIF1α: A Novel Biomarker with Potential Prognostic and Immunotherapy in Pan-cancer.

Authors:  Yonggang Tian; Feihu Bai; Dekui Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-07-08       Impact factor: 7.310

2.  Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma.

Authors:  Bo Zhang; Jilong Zhao; Bing Liu; Yanan Shang; Fei Chen; Sidi Zhang; Jiayao He; Yumei Fan; Ke Tan
Journal:  Front Mol Biosci       Date:  2022-06-30

3.  Circular RNA circNFKB1 promotes osteoarthritis progression through interacting with ENO1 and sustaining NF-κB signaling.

Authors:  Su'an Tang; Xiaoyu Nie; Jianzhao Ruan; Yumei Cao; Jingliang Kang; Changhai Ding
Journal:  Cell Death Dis       Date:  2022-08-09       Impact factor: 9.685

4.  Long non-coding RNA ZNF674-AS1 antagonizes oxaliplatin resistance of gastric cancer via regulating EZH2-mediated methylation of CHST7.

Authors:  Kun Ye; Yong Wang
Journal:  Aging (Albany NY)       Date:  2022-07-08       Impact factor: 5.955

Review 5.  The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer.

Authors:  Xiaoge Hu; Xiangxiang Lei; Jinhui Guo; Wen Fu; Wen Sun; Qiliang Lu; Wei Su; Qiuran Xu; Kangsheng Tu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

6.  Construction and validation of a prognostic model with RNA binding protein-related mRNAs for the HBV-related hepatocellular carcinoma patients.

Authors:  Shaohua Xu; Hui Liu; Renyun Tian; Jiahui Xie; Su Chen; Junyun Luo; Haizhen Zhu; Yirong Wang; Zhaoyong Li
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.